axinn

Axinn Advised Thermo Fisher on \$12.5B Acquisition of QIAGEN

NEWS | LESS THAN 1 MIN READ

March 3, 2020

Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed \$12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.

Related People

Mark D. Alexander John D. Harkrider Michael L. Keeley

Related Services

Antitrust

To subscribe to our publications, <u>click here</u>.

Featured Insights

- GCR Live: Law Leaders Europe 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
 SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
 WEBINAR ANTITRUST
- NJSBA Annual Meeting and Convention 2025
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
 sponsorship ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
 SPEAKING ENGAGEMENT ANTITRUST
- AHLA Health Care Transactions Program 2025
 sponsorship ANTITRUST
- IAM Live: Auto IP USA 2025
 SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- ACI 21st Annual Paragraph IV Conference SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY